|
[Related PubMed/MEDLINE]
Total Number of Papers: 867
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: sEH |
| Long Form |
: soluble epoxide hydrolase |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2022 |
|
AA, CAP, CAT, SHR |
| 2 |
2022 |
|
AFB1 |
| 3 |
2022 |
|
FAAH, SAR |
| 4 |
2022 |
|
AAV, CNV, nAMD |
| 5 |
2022 |
|
CHF, CI, EET, HR, T2D |
| 6 |
2022 |
A Combined Chronic Low-Dose Soluble Epoxide Hydrolase and Acetylcholinesterase Pharmacological Inhibition Promotes Memory Reinstatement in Alzheimer's Disease Mice Models. |
AChE, AD, BDNF, GFAP, IL-6, pCREB, PSD-95, SAMP8, Trem2 |
| 7 |
2022 |
A Distinct Metabolically Defined Central Nucleus Circuit Bidirectionally Controls Anxiety-Related Behaviors. |
BNST, CeA, PUFAs |
| 8 |
2022 |
A hypothesis-driven study to comprehensively investigate the association between genetic polymorphisms in EPHX2 gene and cardiovascular diseases: Findings from the UK Biobank. |
CVDs, EETs |
| 9 |
2022 |
Adeno-associated virus-mediated in vivo suppression of expression of EPHX2 gene modulates the activity of paraventricular nucleus neurons in spontaneously hypertensive rats. |
Ang II, EETs, GFAP, PVN, SHRs, SR, WKY |
| 10 |
2022 |
Age-dependent cognitive impairment, hydrocephalus and leukocyte infiltration in transgenic mice with endothelial expression of human EPHX2. |
CCAO, ED, VCI |
| 11 |
2022 |
Anti-Inflammatory Activity of Soluble Epoxide Hydrolase Inhibitors Based on Selenoureas Bearing an Adamantane Moiety. |
--- |
| 12 |
2022 |
Anti-nociceptive efficacy of the soluble epoxide hydrolase inhibitor t-TUCB in horses with mechanically induced lameness. |
a-HBS, t-TUCB, VAS |
| 13 |
2022 |
Cardiomyocyte-specific disruption of soluble epoxide hydrolase limits inflammation to preserve cardiac function. |
EpFAs, LPS, NLRP3 |
| 14 |
2022 |
CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. |
CES2, PDAC |
| 15 |
2022 |
Compilation and evaluation of a fatty acid mimetics screening library. |
FAMs, FFAR1, LTA4H, PPARgamma, RXRalpha |
| 16 |
2022 |
COX-2/sEH Dual Inhibitor Alleviates Hepatocyte Senescence in NAFLD Mice by Restoring Autophagy through Sirt1/PI3K/AKT/mTOR. |
ARA, COX-2, HFD, NAFLD, PA |
| 17 |
2022 |
COX-2/sEH Dual Inhibitor PTUPB Alleviates CCl 4 -Induced Liver Fibrosis and Portal Hypertension. |
CK-19, COX-2, eNOS, GCH1, IL-6, PHT, PP, PTUPB, SMA, TGF-beta, VEGF, vWF |
| 18 |
2022 |
COX-2/sEH Dual Inhibitor PTUPB Attenuates Epithelial-Mesenchymal Transformation of Alveolar Epithelial Cells via Nrf2-Mediated Inhibition of TGF-β1/Smad Signaling. |
AECs, alpha-SMA, ARA, BLM, COX-2, EMT, PF, TGF |
| 19 |
2022 |
Crosstalk between adenosine receptors and CYP450-derived oxylipins in the modulation of cardiovascular, including coronary reactive hyperemic response. |
A1AR, A3AR, AA, CAD, CRH, CVDs, DHETs, EETs, LA, WT |
| 20 |
2022 |
CYP450 Epoxygenase Metabolites, Epoxyeicosatrienoic Acids, as Novel Anti-Inflammatory Mediators. |
AA, DHETs, EETs |
| 21 |
2022 |
Designing a Small Fluorescent Inhibitor to Investigate Soluble Epoxide Hydrolase Engagement in Living Cells. |
CNS, NBD-Cl |
| 22 |
2022 |
Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease. |
AChE, AD |
| 23 |
2022 |
Discovery and Optimization of Indoline-Based Compounds as Dual 5-LOX/sEH Inhibitors: In Vitro and In Vivo Anti-Inflammatory Characterization. |
5-LOX |
| 24 |
2022 |
Discovery and Optimization of Piperazine Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors. |
mPGES-1 |
| 25 |
2022 |
Discovery of benzamide derivatives containing urea moiety as soluble epoxide hydrolase inhibitors. |
--- |
| 26 |
2022 |
Dissecting the Regulation of Arachidonic Acid Metabolites by Uncaria rhynchophylla (Miq). Miq. in Spontaneously Hypertensive Rats and the Predictive Target sEH in the Anti-Hypertensive Effect Based on Metabolomics and Molecular Docking. |
EETs, SHRs, URE |
| 27 |
2022 |
Effects of cyclooxygenase and soluble epoxide hydrolase inhibitors on apoptosis of cultured primary equine chondrocytes. |
COX, ER |
| 28 |
2022 |
Eicosanoid lipidome activation in post-mortem brain tissues of individuals with APOE4 and Alzheimer's dementia. |
5-LOX, AD, APOE4, cPLA2, DPA, EPA, NPD1, ROS |
| 29 |
2022 |
Epoxyeicosatrienoic acids and soluble epoxide hydrolase in physiology and diseases of the central nervous system. |
CNS, EETs |
| 30 |
2022 |
Epoxyeicosatrienoic Acids Inhibit the Activation of Murine Fibroblasts by Blocking the TGF-β1-Smad2/3 Signaling in a PPARγ-Dependent Manner. |
EETs, PF |
| 31 |
2022 |
Genetic analyses of circulating PUFA-derived mediators identifies heritable dihydroxyeicosatrienoic acid species. |
DHET |
| 32 |
2022 |
Hemodialysis and Plasma Oxylipin Biotransformation in Peripheral Tissue. |
ESRD, HD, LOX |
| 33 |
2022 |
Hyperhomocysteinemia dysregulates plasma levels of polyunsaturated fatty acids-derived eicosanoids. |
AA, COX, CVD, EETs, HHcy, PUFA, WT |
| 34 |
2022 |
Identifying simultaneous matrix metalloproteinases/soluble epoxide hydrolase inhibitors. |
MMP |
| 35 |
2022 |
Inhibitors of soluble epoxide hydrolase on acute lung injury: a meta-analysis of preclinical studies. |
ALI |
| 36 |
2022 |
Inhibitory Activity of Quaternary Isoquinoline Alkaloids on Soluble Epoxide Hydrolase. |
--- |
| 37 |
2022 |
Kurarinone alleviated Parkinson's disease via stabilization of epoxyeicosatrienoic acids in animal model. |
KO, MPTP, PD, SN, STR, TH |
| 38 |
2022 |
Machine Learning on DNA-Encoded Library Count Data Using an Uncertainty-Aware Probabilistic Loss Function. |
DEL, QSAR |
| 39 |
2022 |
New pyrimidine/thiazole hybrids endowed with analgesic, anti-inflammatory, and lower cardiotoxic activities: Design, synthesis, and COX-2/sEH dual inhibition. |
COX |
| 40 |
2022 |
Plasma Oxylipins and Their Precursors Are Strongly Associated with COVID-19 Severity and with Immune Response Markers. |
AA, ICU, LA, PUFA |
| 41 |
2022 |
Quinazoline-4(3H)-one-7-carboxamide Derivatives as Human Soluble Epoxide Hydrolase Inhibitors with Developable 5-Lipoxygenase Activating Protein Inhibition. |
EETs |
| 42 |
2022 |
Redox Regulation of Soluble Epoxide Hydrolase-Implications for Cardiovascular Health and Disease. |
--- |
| 43 |
2022 |
Repositioning of Quinazolinedione-Based Compounds on Soluble Epoxide Hydrolase (sEH) through 3D Structure-Based Pharmacophore Model-Driven Investigation. |
Hsp90 |
| 44 |
2022 |
Repurposing of digoxin in pain and inflammation: An evidence-based study. |
--- |
| 45 |
2022 |
Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs. |
CVD, EETs |
| 46 |
2022 |
Role of the soluble epoxide hydrolase in the hair follicle stem cell homeostasis and hair growth. |
PUFAs |
| 47 |
2022 |
Screening and Identification of Novel Soluble Epoxide Hydrolase Inhibitors from Corn Gluten Peptides. |
--- |
| 48 |
2022 |
Sexual dimorphism in renal heme oxygenase-1 and arachidonic acid metabolizing enzymes in spontaneously hypertensive rats versus normotensive Wistar Kyoto rats. |
20-HETE, BP, COX-2, CYP4A, EETs, HO, HO-1, PGE2, SHR, TBARS |
| 49 |
2022 |
SMTP-44D Exerts Antioxidant and Anti-Inflammatory Effects through Its Soluble Epoxide Hydrolase Inhibitory Action in Immortalized Mouse Schwann Cells upon High Glucose Treatment. |
DHETs, DN, EETs, RAGE, SMTP-44D |
| 50 |
2022 |
Soluble Epoxide Hydrolase Deletion Limits High-Fat Diet-Induced Inflammation. |
--- |
| 51 |
2022 |
Soluble epoxide hydrolase inhibition avoid formalin-induced inflammatory hyperalgesia in the temporomandibular joint. |
EETs, ELISA, IL-10, TMJ |
| 52 |
2022 |
Soluble Epoxide Hydrolase Inhibition Protected against Diabetic Cardiomyopathy through Inducing Autophagy and Reducing Apoptosis Relying on Nrf2 Upregulation and Transcription Activation. |
DCM, HGHF |
| 53 |
2022 |
Soluble Epoxide Hydrolase Inhibitor t-AUCB Ameliorates Vascular Endothelial Dysfunction by Influencing the NF-κB/miR-155-5p/eNOS/NO/IκB Cycle in Hypertensive Rats. |
EETs |
| 54 |
2022 |
Soluble epoxide hydrolase inhibitor, TPPU, attenuates progression of atherosclerotic lesions and vascular smooth muscle cell phenotypic switching. |
NOX4, VSMCs |
| 55 |
2022 |
Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade. |
EFAs, sEHIs |
| 56 |
2022 |
Soluble Epoxide Hydrolase Is Associated with Postprandial Anxiety Decrease in Healthy Adult Women. |
AN, BMI, HW |
| 57 |
2022 |
Structure-guided discovery of potent and oral soluble epoxide hydrolase inhibitors for the treatment of neuropathic pain. |
--- |
| 58 |
2022 |
Synthesis and biological evaluation of new series of benzamide derivatives containing urea moiety as sEH inhibitors. |
--- |
| 59 |
2022 |
Synthesis and structure-activity relationships for some novel diflapolin derivatives with benzimidazole subunit. |
GI, SAR |
| 60 |
2022 |
Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors. |
sEHI |
| 61 |
2022 |
Targeting IRE1α-JNK-c-Jun/AP-1-sEH Signaling Pathway Improves Myocardial and Coronary Endothelial Function Following Global Myocardial Ischemia/Reperfusion. |
ER, I/R, LVEDP, LVSP |
| 62 |
2022 |
The Modulation of Arachidonic Acid Metabolism and Blood Pressure-Lowering Effect of Honokiol in Spontaneously Hypertensive Rats. |
AA, HON, SHR |
| 63 |
2022 |
Therapeutic potential of mangiferin against kidney disorders and its mechanism of action: A review. |
NF-kappaB |
| 64 |
2022 |
Unprecedented diterpenoid dimers with soluble epoxide hydrolase inhibitory effect from Euphorbia fischeriana. |
--- |
| 65 |
2021 |
2-(Piperidin-4-yl)acetamides as Potent Inhibitors of Soluble Epoxide Hydrolase with Anti-Inflammatory Activity. |
sEHI |
| 66 |
2021 |
A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage. |
CSF, DCI, DHETs, EETs, SAH |
| 67 |
2021 |
A thiol redox sensor in soluble epoxide hydrolase enables oxidative activation by intra-protein disulfide bond formation. |
DHETs, EETs |
| 68 |
2021 |
Activating endogenous resolution pathways by soluble epoxide hydrolase inhibitors for the management of COVID-19. |
sEHIs |
| 69 |
2021 |
Activity of sEH and Oxidant Status during Systemic Bovine Coliform Mastitis. |
--- |
| 70 |
2021 |
Adenosine A2A receptor and vascular response: role of soluble epoxide hydrolase, adenosine A1 receptor and angiotensin-II. |
A1AR, Ang II |
| 71 |
2021 |
Adrenic Acid-Derived Epoxy Fatty Acids Are Naturally Occurring Lipids and Their Methyl Ester Prodrug Reduces Endoplasmic Reticulum Stress and Inflammatory Pain. |
DHDTs, EDTs, EpFAs, ER, PUFA |
| 72 |
2021 |
ANTIHYPERTENSIVE AND CARDIOPROTECTIVE EFFECTS OF EPOXYEICOSATRIENOIC ACID ANALOGS AND SOLUBLE EPOXIDE HYDROLASE INHIBITORS (REVIEW). |
AH, Dss, EETs, sEHI, VE |
| 73 |
2021 |
Bisfischoids A and B, dimeric ent-abietane-type diterpenoids with anti-inflammatory potential from Euphorbia fischeriana Steud. |
--- |
| 74 |
2021 |
Cyp2c44 epoxygenase-derived epoxyeicosatrienoic acids in vascular smooth muscle cells elicit vasoconstriction of the murine ophthalmic artery. |
EETs, VSMC |
| 75 |
2021 |
Cytochrome P450-epoxygenated fatty acids inhibit Muller glial inflammation. |
DR, EDP, EET, MC, PA |
| 76 |
2021 |
Deletion of soluble epoxide hydrolase suppressed chronic kidney disease-related vascular calcification by restoring Sirtuin 3 expression. |
ATP, CKD, CVD, EETs, Sirt3, VSMCs, WT |
| 77 |
2021 |
Differential Effects of 17,18-EEQ and 19,20-EDP Combined with Soluble Epoxide Hydrolase Inhibitor t-TUCB on Diet-Induced Obesity in Mice. |
19,20-EDP, BAT, TG |
| 78 |
2021 |
Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice. |
DIO, FXR, NAFLD, NASH |
| 79 |
2021 |
Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis. |
--- |
| 80 |
2021 |
Discovery of novel heterocyclic amide-based inhibitors: an integrative in-silico approach to targeting soluble epoxide hydrolase. |
--- |
| 81 |
2021 |
Discovery of soluble epoxide hydrolase inhibitors through DNA-encoded library technology (ELT). |
ELT |
| 82 |
2021 |
DPP4 inhibitor reduces portal hypertension in cirrhotic rats by normalizing arterial hypocontractility. |
DPP-4i, EET, NE, NOX, ROS |
| 83 |
2021 |
Dual sEH/COX-2 Inhibition Using PTUPB-A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity. |
COX-2 |
| 84 |
2021 |
EETs/sEHi alleviates nociception by blocking the crosslink between endoplasmic reticulum stress and neuroinflammation in a central poststroke pain model. |
CPSP, EETs, ER, LPS, MAPK, PWMT, sEHi, VPL |
| 85 |
2021 |
Eicosanoid regulation of debris-stimulated metastasis. |
EP4 |
| 86 |
2021 |
Endothelial Nox4 dysfunction aggravates atherosclerosis by inducing endoplasmic reticulum stress and soluble epoxide hydrolase. |
4-PBA, ECs, ER, TPPU, VCAM-1 |
| 87 |
2021 |
Epoxyeicosatrienoic Acids and Fibrosis: Recent Insights for the Novel Therapeutic Strategies. |
ARA, DHETs, EETs |
| 88 |
2021 |
Epoxylipids and soluble epoxide hydrolase in heart diseases. |
--- |
| 89 |
2021 |
Evaluating the protective effects of individual or combined ginsenoside compound K and the downregulation of soluble epoxide hydrolase expression against sodium valproate-induced liver cell damage. |
GCK, SVP |
| 90 |
2021 |
First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET. |
PET |
| 91 |
2021 |
From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis. |
sEHIs |
| 92 |
2021 |
Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase/fatty acid amide hydrolase inhibitors. |
EETs, FAAH |
| 93 |
2021 |
Genetic deficiency or pharmacological inhibition of soluble epoxide hydrolase ameliorates high fat diet-induced pancreatic β-cell dysfunction and loss. |
EETs |
| 94 |
2021 |
Ibuprofen alters epoxide hydrolase activity and epoxy-oxylipin metabolites associated with different metabolic pathways in murine livers. |
COX, mEH, NSAIDs |
| 95 |
2021 |
IGF1R signaling regulates astrocyte-mediated neurovascular coupling in mice: implications for brain aging. |
EETs, IGF-1, NVC, VCI |
| 96 |
2021 |
In Vitro and In Silico Studies of Soluble Epoxide Hydrolase Inhibitors from the Roots of Lycopus lucidus. |
--- |
| 97 |
2021 |
Inhibition of sEH via stabilizing the level of EETs alleviated Alzheimer's disease through GSK3β signaling pathway. |
AD, CNS, EETs |
| 98 |
2021 |
Inhibition of soluble epoxide hydrolase (sEH) protects hippocampal neurons and reduces cognitive decline in type 2 diabetic mice. |
EETs, NR2B, PSD-95, Pyk2, t-AUCB |
| 99 |
2021 |
Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney. |
EET, HF-HS, SGLT2, TPPU |
| 100 |
2021 |
Inhibition of Soluble Epoxide Hydrolase Ameliorates Phenotype and Cognitive Abilities in a Murine Model of Niemann Pick Type C Disease. |
EpFAs, EPM, LAMP-1, NORT, Npc, NPC, OF, OLT, OS, sEHI |
|
A Search Service for Abbreviation / Long Form
